Their research demonstrates that targeting T-cell glutamine metabolism through drugs such as C381 or JHU083, or by adoptively transferring inducible GLS1 shRNA-expressing OT-I Teff cells into tumors, not only increases the number of OT-I Teff cells within the TME but also significantly reduces tumor growth and prolongs survival in animal models (15, 16). Here, GLS is linked to neoplasm.